Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Syros Pharmaceuticals (SYRS)
NASDAQ:SYRS
Syros Pharmaceuticals (SYRS) Stock Price & Analysis
872 Followers
SYRS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.09 - $8.17
Previous Close$5.56
Volume287.41K
Average Volume (3M)222.31K
Market Cap
$141.53M
Enterprise Value$64.08M
Total Cash (Recent Filing)$139.53M
Total Debt (Recent Filing)$62.08M
Price to Earnings (P/E)-1.0
Beta0.48
Next Earnings
May 02, 2024EPS Estimate
-$0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.77
Shares Outstanding26,453,891
10 Day Avg. Volume315,715
30 Day Avg. Volume222,307
Standard Deviation0.34
R-Squared0.07
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)8.49
Price to Sales (P/S)380.06
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.45
Enterprise Value/Gross Profit6.45
Enterprise Value/Ebitda-0.41
Forecast
1Y Price Target
$13.33Price Target Upside139.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Syros Pharmaceuticals News
PremiumPre-Earnings
Is SYRS a Buy, Before Earnings?
Ownership Overview
24.69% Insiders
3.76% Mutual Funds
3.55% Other Institutional Investors
68.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SYRS FAQ
What was Syros Pharmaceuticals’s price range in the past 12 months?
Syros Pharmaceuticals lowest stock price was $2.09 and its highest was $8.17 in the past 12 months.
What is Syros Pharmaceuticals’s market cap?
Currently, no data Available
When is Syros Pharmaceuticals’s upcoming earnings report date?
Syros Pharmaceuticals’s upcoming earnings report date is May 02, 2024 which is in 14 days.
How were Syros Pharmaceuticals’s earnings last quarter?
Syros Pharmaceuticals released its earnings results on Mar 27, 2024. The company reported -$2.18 earnings per share for the quarter, missing the consensus estimate of -$1.144 by -$1.036.
Is Syros Pharmaceuticals overvalued?
According to Wall Street analysts Syros Pharmaceuticals’s price is currently Undervalued.
Does Syros Pharmaceuticals pay dividends?
Syros Pharmaceuticals does not currently pay dividends.
What is Syros Pharmaceuticals’s EPS estimate?
Syros Pharmaceuticals’s EPS estimate is -$0.85.
How many shares outstanding does Syros Pharmaceuticals have?
Syros Pharmaceuticals has 26,453,892 shares outstanding.
What happened to Syros Pharmaceuticals’s price movement after its last earnings report?
Syros Pharmaceuticals reported an EPS of -$2.18 in its last earnings report, missing expectations of -$1.144. Following the earnings report the stock price went down -6.56%.
Which hedge fund is a major shareholder of Syros Pharmaceuticals?
Among the largest hedge funds holding Syros Pharmaceuticals’s share is Flagship Pioneering Inc.. It holds Syros Pharmaceuticals’s shares valued at 10M.
---
Syros Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.33 (139.75% Upside)
$13.33 (139.75% Upside)
Blogger Sentiment
Bullish
SYRS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 300.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 9.9%
Last 30 Days ▼ 9.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.14%
12-Months-Change
Fundamentals
Return on Equity
-227.94%
Trailing 12-Months
Asset Growth
-31.21%
Trailing 12-Months
Company Description
Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
---
SYRS Earnings Call
Q4 2024
0:00 / 0:00
---
SYRS Stock 12 Months Forecast
Average Price Target
$13.33
▲(139.75% Upside)
Technical Analysis
MacroGenics
―
Protagonist Therapeutics
―
Crispr Therapeutics AG
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering SYRS
1 Year
1 Year Success Rate
8/22 ratings generated profit
1 Year Average Return
-14.32%
reiterated a buy rating 22 days ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -14.32% per trade.
---